RecruitingNot ApplicableNCT07447531

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

Evaluating Iron-Dependent Biomarkers of Malignant Glioma (WHO Grade IV) Progression

Sponsor

John M. Buatti

Enrollment

15 participants

Start Date

Oct 3, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Glioma

Summary

This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.

Eligibility

Min Age: 21 Years

Inclusion Criteria4

Age > 21 years
New pathologically confirmed diagnosis of WHO grade IV malignant glioma
KPS > 60
Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol

Exclusion Criteria3

History of previous malignancy other than non-melanoma skin cancer in the previous 5 years
History of iron metabolic disorder such as hemochromatosis
Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices

Interested in this trial?

Get notified about updates and connect with the research team.